June 2024 update to my all-time favorite chart from Mark J. Perry American Enterprise Institute Services vs. manufacturing? Gov't vs. free market? Domestic vs. int'l competition? #Healthcare/education vs. everything? P.S. Sorry, #DPFE. Prescription #drugs are only 11% of Medicare Care index Source: https://drugch.nl/46nMkWc
Drug Channels Institute, an HMP Global Company
E-Learning Providers
Philadelphia, PA 6,163 followers
Leading provider of market intelligence, analysis, & expert insights for the pharmaceutical and healthcare supply chain.
About us
Drug Channels Institute, an HMP Global Company, is a leading source of industry research about pharmaceutical economics and the drug distribution system. DCI helps its customers make sense of pharmaceutical economics and the increasingly complex pharmacy distribution and reimbursement system. To learn more about its products, visit drugchannelsinstitute.com. Access Dr. Fein’s popular Drug Channels blog at drugchannels.net.
- Website
-
http://drugchannelsinstitute.com/
External link for Drug Channels Institute, an HMP Global Company
- Industry
- E-Learning Providers
- Company size
- 2-10 employees
- Headquarters
- Philadelphia, PA
- Type
- Privately Held
- Founded
- 2012
- Specialties
- Pharmaceutical economics, 340B Drug Pricing Program, Medicare, Inflation Reduction Act of 2022, Market Access, Benefit Design, Pharmacy, Reimbursement, Biosimilars, Channel management, Medicaid, Specialty drugs, Copay accumulators, PBMs, Pharmacy benefit management, Buy-and-Bill, and Discount cards
Locations
-
Primary
Get directions
1515 Market Street, Suite 1660
Philadelphia, PA 19102, US
Employees at Drug Channels Institute, an HMP Global Company
Updates
-
From Cencora | Pharma solutions: Crafting Effective, Patient-Centric Channel Strategies Learn more about Cencora’s manufacturer solutions: https://drugch.nl/4cUMgje Read the article: https://drugch.nl/3WjQkT5 #sponsored
-
-
Whoa. The COVID-19 pandemic pummeled #physician revenues. #Oncology was hit hard and remained -5.4% below prepandemic baseline as of mid-2022. (Likely due to delayed screening and diagnoses.) Health Affairs ==> https://drugch.nl/3XUZ6JU
-
-
More unintended consequences? FDA regulatory pathways will affect #IRA price setting of RNA-based therapies NDAs for siRNA/RNAi products (7 years) vs. BLAs for other gene therapies & mRNA-based products (11 years) Avalere ==> https://drugch.nl/3zFW41M
-
-
Heads up: New House Oversight report on #PBMs dropped today. Another spicy take on #GrossToNetBubble problems for patients & payers P.S. Again flattered by many cites to DCI's reports & articles 🙏🏻 Full report ==> https://drugch.nl/46jcJor
-
-
Gross-to-Net Bubble Update: 2023 Pricing Realities at 10 Top Drugmakers Details on list and net prices at Bristol Myers Squibb, Eli Lilly & Company, Genentech, GSK, Merck, Novo Nordisk, Sanofi, Takeda, Teva Pharmaceuticals, and UCB ==> https://drugch.nl/3LBJ0gQ
-
-
Fantastic new analysis from Antonio Ciaccia 46brooklyn Research finds that Mark Cuban Mark Cuban Cost Plus Drug Company, PBC selling price is cheaper than (1) Part D plans' total price, and (2) patient out-of-pocket for *preferred* #drugs. Wow. 🤯 ==> https://drugch.nl/3LxmGFd
-
-
More #NADAC craziness: June bounceback in #generic #drug price index has reversed for July. Is NADAC becoming an unstable foundation for the retail pharmacy cost-plus revolution? h/t 46brooklyn Research & Nephron Research LLC
-
-
Have you requested an invite to the inaugural Drug Channels Leadership Forum #DCLF2025? Attendance will be highly limited, so apply now. ==> https://drugch.nl/DCLF Fireside chat headliners below. 👇Full agenda coming in early September! HMP Global
-
-
Per Navitus Health Solutions 2023 #PBM #Drug Trend Report, non-specialty comm'l drug spending +7.9% (+5.1% w/o GLP-1s) Specialty: +5.7% (unit costs -4.9% *excluding* payer savings from accumulators & maximizers) P.S. Kudos for releasing a report! ==> https://drugch.nl/3W88jMn
-